vs
ADMA BIOLOGICS, INC.（ADMA）与Priority Technology Holdings, Inc.（PRTH）财务数据对比。点击上方公司名可切换其他公司
Priority Technology Holdings, Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.8倍（$247.1M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 3.6%，领先31.9%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 8.8%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $30.9M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 9.6%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Priority Technology Holdings, Inc.是一家聚焦信息技术领域的企业，业务围绕计算机、通信系统等相关信息设备展开，涵盖信息的创建、处理、存储、检索与传输等相关信息技术应用服务，依托计算机科学与工程技术支撑业务开展。
ADMA vs PRTH — 直观对比
营收规模更大
PRTH
是对方的1.8倍
$139.2M
营收增速更快
ADMA
高出9.6%
8.8%
净利率更高
ADMA
高出31.9%
3.6%
自由现金流更多
ADMA
多$3.7M
$30.9M
两年增速更快
ADMA
近两年复合增速
9.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $247.1M |
| 净利润 | $49.4M | $8.9M |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | 13.6% |
| 净利率 | 35.5% | 3.6% |
| 营收同比 | 18.4% | 8.8% |
| 净利润同比 | -55.9% | 23.9% |
| 每股收益（稀释后） | $0.20 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAPRTH
| Q4 25 | $139.2M | $247.1M | ||
| Q3 25 | $134.2M | $241.4M | ||
| Q2 25 | $122.0M | $239.8M | ||
| Q1 25 | $114.8M | $224.6M | ||
| Q4 24 | $117.5M | $227.1M | ||
| Q3 24 | $119.8M | $227.0M | ||
| Q2 24 | $107.2M | $219.9M | ||
| Q1 24 | $81.9M | $205.7M |
净利润ADMAPRTH
| Q4 25 | $49.4M | $8.9M | ||
| Q3 25 | $36.4M | $27.6M | ||
| Q2 25 | $34.2M | $10.9M | ||
| Q1 25 | $26.9M | $8.3M | ||
| Q4 24 | $111.9M | $7.2M | ||
| Q3 24 | $35.9M | $10.6M | ||
| Q2 24 | $32.1M | $994.0K | ||
| Q1 24 | $17.8M | $5.2M |
毛利率ADMAPRTH
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
营业利润率ADMAPRTH
| Q4 25 | 45.1% | 13.6% | ||
| Q3 25 | 38.0% | 15.6% | ||
| Q2 25 | 35.1% | 15.6% | ||
| Q1 25 | 30.4% | 14.5% | ||
| Q4 24 | 32.6% | 15.0% | ||
| Q3 24 | 33.1% | 16.8% | ||
| Q2 24 | 36.6% | 15.1% | ||
| Q1 24 | 26.7% | 13.6% |
净利率ADMAPRTH
| Q4 25 | 35.5% | 3.6% | ||
| Q3 25 | 27.1% | 11.4% | ||
| Q2 25 | 28.1% | 4.5% | ||
| Q1 25 | 23.4% | 3.7% | ||
| Q4 24 | 95.2% | 3.2% | ||
| Q3 24 | 30.0% | 4.7% | ||
| Q2 24 | 29.9% | 0.5% | ||
| Q1 24 | 21.7% | 2.5% |
每股收益（稀释后）ADMAPRTH
| Q4 25 | $0.20 | $0.10 | ||
| Q3 25 | $0.15 | $0.34 | ||
| Q2 25 | $0.14 | $0.14 | ||
| Q1 25 | $0.11 | $0.10 | ||
| Q4 24 | $0.45 | $-0.05 | ||
| Q3 24 | $0.15 | $0.07 | ||
| Q2 24 | $0.13 | $-0.23 | ||
| Q1 24 | $0.08 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $77.2M |
| 总债务越低越好 | $72.1M | $1.0B |
| 股东权益账面价值 | $477.3M | $-100.4M |
| 总资产 | $624.2M | $2.4B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAPRTH
| Q4 25 | $87.6M | $77.2M | ||
| Q3 25 | $61.4M | $57.0M | ||
| Q2 25 | $90.3M | $50.6M | ||
| Q1 25 | $71.6M | $47.6M | ||
| Q4 24 | $103.1M | $58.6M | ||
| Q3 24 | $86.7M | $41.1M | ||
| Q2 24 | $88.2M | $34.6M | ||
| Q1 24 | $45.3M | $34.3M |
总债务ADMAPRTH
| Q4 25 | $72.1M | $1.0B | ||
| Q3 25 | $72.4M | $997.5M | ||
| Q2 25 | — | $917.0M | ||
| Q1 25 | — | $918.9M | ||
| Q4 24 | $72.3M | $920.9M | ||
| Q3 24 | — | $808.1M | ||
| Q2 24 | — | $809.0M | ||
| Q1 24 | — | $631.4M |
股东权益ADMAPRTH
| Q4 25 | $477.3M | $-100.4M | ||
| Q3 25 | $431.2M | $-110.3M | ||
| Q2 25 | $398.3M | $-146.1M | ||
| Q1 25 | $373.4M | $-158.3M | ||
| Q4 24 | $349.0M | $-166.8M | ||
| Q3 24 | $231.9M | $-165.8M | ||
| Q2 24 | $188.3M | $-172.1M | ||
| Q1 24 | $153.7M | $-159.9M |
总资产ADMAPRTH
| Q4 25 | $624.2M | $2.4B | ||
| Q3 25 | $568.7M | $2.2B | ||
| Q2 25 | $558.4M | $2.0B | ||
| Q1 25 | $510.6M | $1.9B | ||
| Q4 24 | $488.7M | $1.8B | ||
| Q3 24 | $390.6M | $1.8B | ||
| Q2 24 | $376.4M | $1.7B | ||
| Q1 24 | $350.9M | $1.6B |
负债/权益比ADMAPRTH
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $36.8M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $30.9M |
| 自由现金流率自由现金流/营收 | 24.8% | 12.5% |
| 资本支出强度资本支出/营收 | 0.8% | 2.4% |
| 现金转化率经营现金流/净利润 | 0.72× | 4.12× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $75.1M |
8季度趋势，按日历期对齐
经营现金流ADMAPRTH
| Q4 25 | $35.6M | $36.8M | ||
| Q3 25 | $13.3M | $36.1M | ||
| Q2 25 | $21.1M | $17.1M | ||
| Q1 25 | $-19.7M | $10.0M | ||
| Q4 24 | $50.2M | $23.8M | ||
| Q3 24 | $25.0M | $19.8M | ||
| Q2 24 | $45.6M | $28.7M | ||
| Q1 24 | $-2.2M | $13.3M |
自由现金流ADMAPRTH
| Q4 25 | $34.6M | $30.9M | ||
| Q3 25 | $-1.1M | $30.1M | ||
| Q2 25 | $18.7M | $9.2M | ||
| Q1 25 | $-24.4M | $4.9M | ||
| Q4 24 | $47.5M | $19.1M | ||
| Q3 24 | $24.0M | $14.5M | ||
| Q2 24 | $43.6M | $23.6M | ||
| Q1 24 | $-4.6M | $6.7M |
自由现金流率ADMAPRTH
| Q4 25 | 24.8% | 12.5% | ||
| Q3 25 | -0.8% | 12.5% | ||
| Q2 25 | 15.3% | 3.8% | ||
| Q1 25 | -21.2% | 2.2% | ||
| Q4 24 | 40.4% | 8.4% | ||
| Q3 24 | 20.0% | 6.4% | ||
| Q2 24 | 40.7% | 10.7% | ||
| Q1 24 | -5.6% | 3.3% |
资本支出强度ADMAPRTH
| Q4 25 | 0.8% | 2.4% | ||
| Q3 25 | 10.7% | 2.5% | ||
| Q2 25 | 2.0% | 3.3% | ||
| Q1 25 | 4.1% | 2.3% | ||
| Q4 24 | 2.3% | 2.0% | ||
| Q3 24 | 0.9% | 2.3% | ||
| Q2 24 | 1.9% | 2.3% | ||
| Q1 24 | 2.9% | 3.2% |
现金转化率ADMAPRTH
| Q4 25 | 0.72× | 4.12× | ||
| Q3 25 | 0.36× | 1.31× | ||
| Q2 25 | 0.62× | 1.57× | ||
| Q1 25 | -0.73× | 1.20× | ||
| Q4 24 | 0.45× | 3.29× | ||
| Q3 24 | 0.70× | 1.87× | ||
| Q2 24 | 1.42× | 28.87× | ||
| Q1 24 | -0.12× | 2.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PRTH
暂无分部数据
